Article Text

Download PDFPDF
Effect of dapagliflozin on cardiovascular events in patients with type 2 diabetes
  1. Emma Magavern12,
  2. Teck K Khong3
  1. 1 William Harvey Research Institute, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, London, UK
  2. 2 Department of Clinical Pharmacology, Cardiovascular Medicine, Barts Health NHS Trust, London, UK
  3. 3 Clinical Pharmacology, St George's, University of London, London, UK
  1. Correspondence to Dr Teck K Khong, Clinical Pharmacology, St George's University of London, London, UK; tkhong{at}sgul.ac.uk

Abstract

DTB commentaries provide an overview of, and commentary on, a clinical trial, systematic review or observational study.

  • cardiovascular diseases
  • diabetes mellitus
View Full Text

Statistics from Altmetric.com

Footnotes

  • Competing interests None declared. Refer to the online supplementary files to view the ICMJE form(s).

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.